RT Journal Article
SR Electronic
T1 In situ recruitment of regulatory T cells promotes donor-specific tolerance in vascularized composite allotransplantation
JF Science Advances
JO Sci Adv
FD American Association for the Advancement of Science
SP eaax8429
DO 10.1126/sciadv.aax8429
VO 6
IS 11
A1 Fisher, James D.
A1 Zhang, Wensheng
A1 Balmert, Stephen C.
A1 Aral, Ali M.
A1 Acharya, Abhinav P.
A1 Kulahci, Yalcin
A1 Li, Jingjing
A1 Turnquist, Heth R.
A1 Thomson, Angus W.
A1 Solari, Mario G.
A1 Gorantla, Vijay S.
A1 Little, Steven R.
YR 2020
UL http://advances.sciencemag.org/content/6/11/eaax8429.abstract
AB Vascularized composite allotransplantation (VCA) encompasses face and limb transplantation, but as with organ transplantation, it requires lifelong regimens of immunosuppressive drugs to prevent rejection. To achieve donor-specific immune tolerance and reduce the need for systemic immunosuppression, we developed a synthetic drug delivery system that mimics a strategy our bodies naturally use to recruit regulatory T cells (Treg) to suppress inflammation. Specifically, a microparticle-based system engineered to release the Treg-recruiting chemokine CCL22 was used in a rodent hindlimb VCA model. These “Recruitment-MP” prolonged hindlimb allograft survival indefinitely (>200 days) and promoted donor-specific tolerance. Recruitment-MP treatment enriched Treg populations in allograft skin and draining lymph nodes and enhanced Treg function without affecting the proliferative capacity of conventional T cells. With implications for clinical translation, synthetic human CCL22 induced preferential migration of human Treg in vitro. Collectively, these results suggest that Recruitment-MP promote donor-specific immune tolerance via local enrichment of suppressive Treg.